Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CELC
Previous Symbol
CUSIPN/A
Phone763-392-0767
Debt
Debt-to-Equity RatioN/A
Current Ratio24.13
Quick Ratio24.13
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.11 per share
Price / Book7.18
Profitability
EPS (Most Recent Fiscal Year)($0.78)
Net Income$-6,250,000.00
Net MarginsN/A
Return on Equity-24.34%
Return on Assets-23.67%
Miscellaneous
Employees22
Outstanding Shares10,160,000
Market Cap$226.95 million
OptionableNot Optionable
Celcuity (NASDAQ:CELC) Frequently Asked Questions
What is Celcuity's stock symbol?
Celcuity trades on the NASDAQ under the ticker symbol "CELC."
How were Celcuity's earnings last quarter?
Celcuity Inc (NASDAQ:CELC) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.03. View Celcuity's Earnings History.
When is Celcuity's next earnings date?
What price target have analysts set for CELC?
2 brokerages have issued 1 year price targets for Celcuity's stock. Their predictions range from $35.00 to $36.00. On average, they expect Celcuity's share price to reach $35.50 in the next year. This suggests a possible upside of 58.9% from the stock's current price. View Analyst Price Targets for Celcuity.
What is the consensus analysts' recommendation for Celcuity?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celcuity.
Has Celcuity been receiving favorable news coverage?
Media headlines about CELC stock have trended somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celcuity earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are some of Celcuity's key competitors?
Some companies that are related to Celcuity include InVitae (NVTA), RadNet (RDNT), Veracyte (VCYT), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Fulgent Genetics (FLGT), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), OpGen (OPGN), Aeon Global Health (AGHC), Biocept (BIOC) and Foundation Medicine (FMI).
Who are Celcuity's key executives?
Celcuity's management team includes the folowing people:
- Mr. Brian F. Sullivan, Co-Founder, Chairman, CEO & CFO (Age 56)
- Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 56)
- Ms. Vicky Hahne, Chief Financial Officer (Age 52)
- Ms. Laura Beggrow RN, Chief Commercial Officer (Age 55)
- Mr. Larry Fitzgerald, VP of Strategic Partnerships & Managed Markets (Age 47)
When did Celcuity IPO?
(CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.
Who are Celcuity's major shareholders?
Celcuity's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.87%), Vanguard Group Inc. (2.56%), Vanguard Group Inc (2.56%), Gagnon Securities LLC (1.90%), ARS Investment Partners LLC (0.47%) and US Bancorp DE (0.43%). View Institutional Ownership Trends for Celcuity.
Which major investors are selling Celcuity stock?
Which major investors are buying Celcuity stock?
CELC stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., US Bancorp DE, Accredited Investors Inc., Renaissance Technologies LLC, Teachers Advisors LLC, BlackRock Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Celcuity.
How do I buy shares of Celcuity?
Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celcuity's stock price today?
One share of CELC stock can currently be purchased for approximately $22.34.
How big of a company is Celcuity?
Celcuity has a market capitalization of $226.95 million. The company earns $-6,250,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Celcuity employs 22 workers across the globe.
What is Celcuity's official website?
How can I contact Celcuity?
Celcuity's mailing address is 16305 36TH AVENUE N SUITE 450, MINNEAPOLIS MN, 55446. The company can be reached via phone at 763-392-0767.
MarketBeat Community Rating for Celcuity (NASDAQ CELC)
MarketBeat's community ratings are surveys of what our community members think about Celcuity and other stocks. Vote "Outperform" if you believe CELC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELC will underperform the S&P 500 over the long term. You may vote once every thirty days.
